These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

176 related articles for article (PubMed ID: 22027417)

  • 21. Immune-mediated red cell aplasia after anti-CTLA-4 immunotherapy for metastatic melanoma.
    Gordon IO; Wade T; Chin K; Dickstein J; Gajewski TF
    Cancer Immunol Immunother; 2009 Aug; 58(8):1351-3. PubMed ID: 19052742
    [No Abstract]   [Full Text] [Related]  

  • 22. T-cell activation and maturation at tumor site associated with objective response to ipilimumab in metastatic melanoma.
    Del Vecchio M; Mortarini R; Tragni G; Di Guardo L; Bersani I; Di Tolla G; Agustoni F; Colonna V; Weber JS; Anichini A
    J Clin Oncol; 2011 Nov; 29(32):e783-8. PubMed ID: 21990398
    [No Abstract]   [Full Text] [Related]  

  • 23. [Ctla-4 blockade: a new hope for the immunotherapy of malignant melanoma].
    Lotem M; Merims S; Frank S; Ospovat I; Peretz T
    Harefuah; 2012 Oct; 151(10):585-8, 604. PubMed ID: 23316667
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Treating cancer by targeting the immune system.
    Hwu P
    N Engl J Med; 2010 Aug; 363(8):779-81. PubMed ID: 20818880
    [No Abstract]   [Full Text] [Related]  

  • 25. The conquest of melanoma by immunotherapy.
    Lejeune FJ
    Melanoma Res; 2015 Oct; 25(5):373-5. PubMed ID: 26173006
    [No Abstract]   [Full Text] [Related]  

  • 26. CTLA-4-blocking immunotherapy with ipilimumab for advanced melanoma.
    Tarhini AA; Kirkwood JM
    Oncology (Williston Park); 2010 Dec; 24(14):1302, 1304. PubMed ID: 21294474
    [No Abstract]   [Full Text] [Related]  

  • 27. Cancer's off switch.
    Wolchok JD
    Sci Am; 2014 May; 310(5):40-5. PubMed ID: 24783590
    [No Abstract]   [Full Text] [Related]  

  • 28. Immunotherapy in melanoma: Recent advances and future directions.
    Franklin C; Livingstone E; Roesch A; Schilling B; Schadendorf D
    Eur J Surg Oncol; 2017 Mar; 43(3):604-611. PubMed ID: 27769635
    [TBL] [Abstract][Full Text] [Related]  

  • 29. The perspective of immunotherapy: new molecules and new mechanisms of action in immune modulation.
    Blank CU
    Curr Opin Oncol; 2014 Mar; 26(2):204-14. PubMed ID: 24424272
    [TBL] [Abstract][Full Text] [Related]  

  • 30. The antitumor immunity of ipilimumab: (T-cell) memories to last a lifetime?
    Postow MA; Callahan MK; Wolchok JD
    Clin Cancer Res; 2012 Apr; 18(7):1821-3. PubMed ID: 22338019
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Cancer Immunotherapy with Anti-CTLA-4 Monoclonal Antibodies Induces an Inflammatory Bowel Disease.
    Marthey L; Mateus C; Mussini C; Nachury M; Nancey S; Grange F; Zallot C; Peyrin-Biroulet L; Rahier JF; Bourdier de Beauregard M; Mortier L; Coutzac C; Soularue E; Lanoy E; Kapel N; Planchard D; Chaput N; Robert C; Carbonnel F
    J Crohns Colitis; 2016 Apr; 10(4):395-401. PubMed ID: 26783344
    [TBL] [Abstract][Full Text] [Related]  

  • 32. [Orbital myositis associated with ipilimumab].
    Lecouflet M; Verschoore M; Giard C; Gohier P; Le Corre Y; Milea D; Martin L
    Ann Dermatol Venereol; 2013; 140(6-7):448-51. PubMed ID: 23773743
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Anti-CTLA-4 therapy may have mechanisms similar to those occurring in inherited human CTLA4 haploinsufficiency.
    Bakacs T; Mehrishi JN
    Immunobiology; 2015 May; 220(5):624-5. PubMed ID: 25638260
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Patient responses to ipilimumab, a novel immunopotentiator for metastatic melanoma: how different are these from conventional treatment responses?
    Pennock GK; Waterfield W; Wolchok JD
    Am J Clin Oncol; 2012 Dec; 35(6):606-11. PubMed ID: 21336089
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Structural basis for cancer immunotherapy by the first-in-class checkpoint inhibitor ipilimumab.
    Ramagopal UA; Liu W; Garrett-Thomson SC; Bonanno JB; Yan Q; Srinivasan M; Wong SC; Bell A; Mankikar S; Rangan VS; Deshpande S; Korman AJ; Almo SC
    Proc Natl Acad Sci U S A; 2017 May; 114(21):E4223-E4232. PubMed ID: 28484017
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Update on the role of ipilimumab in melanoma and first data on new combination therapies.
    Maio M; Di Giacomo AM; Robert C; Eggermont AM
    Curr Opin Oncol; 2013 Mar; 25(2):166-72. PubMed ID: 23299197
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Overcoming immunologic tolerance to melanoma: targeting CTLA-4 with ipilimumab (MDX-010).
    Weber J
    Oncologist; 2008; 13 Suppl 4():16-25. PubMed ID: 19001147
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Ipilimumab (Yervoy) and the TGN1412 catastrophe.
    Bakacs T; Mehrishi JN; Moss RW
    Immunobiology; 2012 Jun; 217(6):583-9. PubMed ID: 21821307
    [TBL] [Abstract][Full Text] [Related]  

  • 39. QnAs with James Allison.
    Nair P
    Proc Natl Acad Sci U S A; 2016 Aug; 113(33):9131-2. PubMed ID: 27506789
    [No Abstract]   [Full Text] [Related]  

  • 40. Adjuvant Autologous Melanoma Vaccine for Macroscopic Stage III Disease: Survival, Biomarkers, and Improved Response to CTLA-4 Blockade.
    Lotem M; Merims S; Frank S; Hamburger T; Nissan A; Kadouri L; Cohen J; Straussman R; Eisenberg G; Frankenburg S; Carmon E; Alaiyan B; Shneibaum S; Ozge Ayyildiz Z; Isbilen M; Mert Senses K; Ron I; Steinberg H; Smith Y; Shiloni E; Gure AO; Peretz T
    J Immunol Res; 2016; 2016():8121985. PubMed ID: 27294163
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.